Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial
Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial
Hongyun Zhao, Yifan Zhai, Xu Liang, Jinhui Xue et al.
Journal
EClinicalMedicine
Topics
Lung Cancer Treatments and Mutations
article
Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial
Fujian Medical University (CN), Sun Yat-sen University (CN), Peking University (CN), Zhengzhou University (CN), Peking University Cancer Hospital (CN), Zhejiang Cancer Hospital (CN), Hunan Cancer Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Wuhan Union Hospital (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Bridge Pharma (United States) (US), Union Hospital (CN)